Ainos, Inc.
No enriched coverage for $AIMD in the last 7 days.
No SEC Form 4 filings for $AIMD in the last 30 days.
Ainos, Inc. director Lee Ting-chuan reported the acquisition of 570,000 common shares through the conversion of restricted stock units (RSUs) on April 15, 2026. These RSUs were granted and vested under the company's 2023 Stock Incentive Plan, valued at $1.61 per share. Following this transaction, Lee Ting-chuan directly holds 935,707 shares of Ainos common stock.
Ainos, Inc. is expanding its Smell AI deployments, powered by AI Nose, into healthcare infrastructure, collaborating with MacKay Memorial Hospital and Topco Scientific Co., Ltd. This move broadens the application of its technology beyond semiconductor and robotics industries. The expansion positions Smell AI as an integral perception layer for environmental monitoring and safety within hospitals, aiming to convert deployments into repeatable revenue streams throughout 2026, which is identified as a key scale-up phase.
Ainos (NASDAQ:AIMD) is expanding its Smell AI deployments into healthcare infrastructure, including collaborations with MacKay Memorial Hospital and Topco Scientific for environmental monitoring in hospitals. This move builds on its existing applications in semiconductor and robotics industries, reinforcing its AI infrastructure positioning and multi-vertical scalability. The company is also advancing its Smell ID and Smell Language Model to scale a data flywheel for repeatable deployments, aiming to establish Smell AI as a new layer of physical AI.
